This company has been marked as potentially delisted and may not be actively trading. Alterity Therapeutics (PRAN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock PRAN vs. LITS, WHWK, OSTX, ELYM, ATNM, AADI, NBRV, EGRX, PYRGF, and TAOXShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Lite Strategy (LITS), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), Aadi Bioscience (AADI), Nabriva Therapeutics (NBRV), Eagle Pharmaceuticals (EGRX), PyroGenesis Canada (PYRGF), and Synaptogenix (TAOX). Alterity Therapeutics vs. Its Competitors Lite Strategy Whitehawk Therapeutics OS Therapies Eliem Therapeutics Actinium Pharmaceuticals Aadi Bioscience Nabriva Therapeutics Eagle Pharmaceuticals PyroGenesis Canada Synaptogenix Alterity Therapeutics (NASDAQ:PRAN) and Lite Strategy (NASDAQ:LITS) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership. Is PRAN or LITS more profitable? Alterity Therapeutics' return on equity of 0.00% beat Lite Strategy's return on equity.Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A Lite Strategy N/A -69.70%-60.80% Do insiders and institutionals hold more shares of PRAN or LITS? 3.6% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Lite Strategy shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 3.1% of Lite Strategy shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, PRAN or LITS? Alterity Therapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Lite Strategy has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Do analysts recommend PRAN or LITS? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has better earnings & valuation, PRAN or LITS? Alterity Therapeutics has higher earnings, but lower revenue than Lite Strategy. Alterity Therapeutics is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity Therapeutics$150K254.54-$6.40M-$0.70-6.13Lite Strategy$65.30M1.17-$15.94M-$4.75-0.45 Does the media prefer PRAN or LITS? In the previous week, Lite Strategy had 5 more articles in the media than Alterity Therapeutics. MarketBeat recorded 5 mentions for Lite Strategy and 0 mentions for Alterity Therapeutics. Lite Strategy's average media sentiment score of 0.51 beat Alterity Therapeutics' score of 0.00 indicating that Lite Strategy is being referred to more favorably in the news media. Company Overall Sentiment Alterity Therapeutics Neutral Lite Strategy Positive SummaryAlterity Therapeutics beats Lite Strategy on 7 of the 13 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAN vs. The Competition Export to ExcelMetricAlterity TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.18M$1.00B$6.04B$10.46BDividend YieldN/A4.84%5.73%4.79%P/E Ratio-6.131.2885.3127.07Price / Sales254.5431.05589.44190.44Price / CashN/A17.6425.7330.17Price / Book3.067.5412.666.69Net Income-$6.40M-$7.59M$3.31B$276.03M Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRANAlterity TherapeuticsN/A$4.29-4.7%N/A+233.9%$38.18M$150K-6.1314Gap DownLITSLite StrategyN/A$2.49+2.9%N/AN/A$88.77M$65.30M-0.52100News CoverageGap DownWHWKWhitehawk Therapeutics0.9949 of 5 stars$1.86-2.1%N/AN/A$87.66M$25.98M-31.0021OSTXOS TherapiesN/A$1.97+0.5%$18.00+813.7%N/A$61.83MN/A-2.47N/AGap DownELYMEliem TherapeuticsN/A$1.99-6.6%N/A-66.8%$59.21MN/A-3.759ATNMActinium Pharmaceuticals1.902 of 5 stars$1.61+0.3%$4.50+180.4%-17.2%$50.07MN/A-1.1530News CoverageAADIAadi BioscienceN/A$1.92-1.0%N/A-1.5%$47.42M$25.07M-0.8440News CoverageNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070EGRXEagle Pharmaceuticals1.3591 of 5 stars$2.70-4.4%N/A+82.9%$35.07M$257.55M0.00100Gap DownPYRGFPyroGenesis Canada0.0683 of 5 stars$0.17+1.3%N/A-69.8%$31.88M$9.14M-2.8390News CoverageGap DownHigh Trading VolumeTAOXSynaptogenix0.1902 of 5 stars$6.71+2.4%N/AN/A$23.42MN/A-0.334News CoverageGap Up Related Companies and Tools Related Companies Lite Strategy Competitors Whitehawk Therapeutics Competitors OS Therapies Competitors Eliem Therapeutics Competitors Actinium Pharmaceuticals Competitors Aadi Bioscience Competitors Nabriva Therapeutics Competitors Eagle Pharmaceuticals Competitors PyroGenesis Canada Competitors Synaptogenix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAN) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
